Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Myriad Genetics (MYGN) Tops Q4 EPS by 5c; Raises Outlook
August 21, 2018 4:08 PM EDTMyriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.38, $0.05 better than the analyst estimate of $0.33. Revenue for the quarter came in at $200.9 million versus the consensus estimate of $195.76 million.
GUIDANCE:
Myriad Genetics sees Q1 2019 EPS of $0.28-$0.30, versus the consensus of... More
